Mylan N.V. (NASDAQ: MYL) today commented on a Warning Letter issued by the U.S. Food and Drug Administration (FDA) on Nov. 9, 2018, relating to its manufacturing facility in Morgantown, West...
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug...
Mylan N.V. (NASDAQ: MYL) today announced its financial results for the quarter and nine months ended September 30, 2018. Third Quarter 2018 Financial Highlights U.S. GAAP diluted earnings per...
Oct. 22, 2018 In response to multiple inquiries received regarding the status of Mylan’s Abbreviated New Drug Application for generic Advair® (Wixela®), Mylan confirms it has not received any...
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has initiated the commercial launch of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets...
Educational materials to help empower your customers.
What to know about our high quality generics.
Details about our brand name and generic medicines.
Resources that meet the specific needs of your institution.
Copyright © 2018 Mylan N.V. All Rights Reserved.
For U.S. Audiences Only
Please select one of our websites from the list below.
Mylan also is proud to do business in these locations.